Deals
Biogen Says It's Back and Ready for ‘Highly Active’ Dealmaking
- $300 million deal with Bristol just the beginning, exec says
- Drugmaker facing competition for multiple sclerosis treatments
This article is for subscribers only.
Biogen Inc. is ready to make some deals.
“We’re moving, and we’re back in terms of augmenting the pipeline,” research and development head Michael Ehlers said Friday in an interview. An agreement last week to pay Bristol-Myers Squibb Co. $300 million upfront for an experimental Alzheimer’s drug is “hopefully just the beginning of a set of very rigorous but highly active deals.”